Tafasitamab XmAb5574; MOR00208; Tafasitamab-cxix|cas:1422527-84-1|西域试剂

Tafasitamab XmAb5574; MOR00208; Tafasitamab-cxix,97.40%

产品编号：Bellancom-P9981| CAS NO：1422527-84-1

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P9981		￥5200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Tafasitamab XmAb5574; MOR00208; Tafasitamab-cxix

产品介绍

Tafasitamab (XmAb5574) 是一种 Fc 修饰的人源化单克隆抗体，可与人 B 细胞表面抗原 CD19 结合。

生物活性

Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.

体外研究

Tafasitamab (XmAb5574) induces cytotoxicity against Mino and Jeko (MCL) cell lines in an E/T ratio-dependent manner. Tafasitamab (XmAb5574) increases ADCP and antiproliferative activity. Tafasitamab (XmAb5574) enhances antiproliferative apoptotic activity due to caspase-induced apoptosis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line:	NHL cell lines and primary CLL and MCL cells by γδ T cells
Concentration:
Incubation Time:	2 h
Result:	Induced killing of NHL cell lines and primary CLL and MCL cells by γδ T cells.

Cell Proliferation Assay

Cell Line:	SU-DHL-6 cells
Concentration:
Incubation Time:	72 h
Result:	Showed potent antiproliferative effects on tumor cell.

Apoptosis Analysis

Cell Line:	SU-DHL-6 cells
Concentration:	0-4 ng/mL
Incubation Time:	48 h
Result:	Showed potent antiproliferative effects due to caspase-induced apoptosis

体内研究
(In Vivo)

Tafasitamab (SC, once on Day 1, 2.5 μg/kg) inhibits lymphoma growth in disseminated BL mouse xenograft tumor models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Disseminated Raji model.
Dosage:	2.5 μg/kg
Administration:	Tafasitamab (SC, once on Day 1, 2.5 μg/kg)
Result:	Showed antitumor activity in disseminated Raji model.

Animal Model:	Disseminated Ramos model.
Dosage:	10 mg/kg
Administration:	Tafasitamab (IV, on Days 3, 6, 10, 13, 17, and 20 at a dose of 10 mg/kg)
Result:	Showed antitumor activity in disseminated Ramos model.

体内研究

Tafasitamab (SC, once on Day 1, 2.5 μg/kg) inhibits lymphoma growth in disseminated BL mouse xenograft tumor models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Disseminated Raji model.
Dosage:	2.5 μg/kg
Administration:	Tafasitamab (SC, once on Day 1, 2.5 μg/kg)
Result:	Showed antitumor activity in disseminated Raji model.

Animal Model:	Disseminated Ramos model.
Dosage:	10 mg/kg
Administration:	Tafasitamab (IV, on Days 3, 6, 10, 13, 17, and 20 at a dose of 10 mg/kg)
Result:	Showed antitumor activity in disseminated Ramos model.

体内研究

Tafasitamab (SC, once on Day 1, 2.5 μg/kg) inhibits lymphoma growth in disseminated BL mouse xenograft tumor models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Disseminated Raji model.
Dosage:	2.5 μg/kg
Administration:	Tafasitamab (SC, once on Day 1, 2.5 μg/kg)
Result:	Showed antitumor activity in disseminated Raji model.

Animal Model:	Disseminated Ramos model.
Dosage:	10 mg/kg
Administration:	Tafasitamab (IV, on Days 3, 6, 10, 13, 17, and 20 at a dose of 10 mg/kg)
Result:	Showed antitumor activity in disseminated Ramos model.